Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

22.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Schrodinger, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
Earnings Scheduled For November 12, 2024
 
Via Benzinga
What Analysts Are Saying About Schrodinger Stock
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
3 Momentum Stocks That Could Soar Post-Market Volatility
Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum? 
Via MarketBeat
Topics Artificial Intelligence World Trade
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3... 
Via Benzinga
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
The 3 Best Med Tech Stocks to Buy Now
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024
SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
3 Small-Cap Stocks to Buy at a 52-Week Low
The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows 
Via InvestorPlace
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
The Fed is widely expected to cut interest rates a great deal. Here are three stocks to buy to benefit from these interest rate cuts. 
Via InvestorPlace
Topics Economy
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
3 Top-Rated Gene Editing Stocks Actually Making Money
Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond. 
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
The global 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
The global 
Via Talk Markets
The 7 AI Categories Were Down 4%, On Average, This Week; Up 1% In May
The 7 AI categories we track dropped, down 4.3% this week, and are now only up 1.3% for the month of May. 
Via Talk Markets
Topics Artificial Intelligence
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS